DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence

Francesca Menghi, Francesca N. Orzan, Marica Eoli, Mariangela Farinotti, Emanuela Maderna, Federica Pisati, Donatella Bianchessi, Lorella Valletta, Sandro Lodrini, Giuseppe Galli, Elena Anghileri, Serena Pellegatta, Bianca Pollo, Finocchiaro Gaetano

Research output: Contribution to journalArticle

Abstract

Meningiomas are the most frequent intracranial tumors. Surgery can be curative, but recurrences are possible. We performed gene expression analyses and loss of heterozygosity (LOH) studies looking for new markers predicting the recurrence risk. We analyzed expression profiles of 23 meningiomas (10 grade I, 10 grade II, and 3 grade III) and validated the data using quantitative polymerase chain reaction (qPCR). We performed LOH analysis on 40 meningiomas, investigating chromosomal regions on 1p, 9p, 10q, 14q, and 22q. We found 233 and 268 probe sets to be significantly down- and upregulated, respectively, in grade II or III meningiomas. Genes downregulated in high-grade meningiomas were overrepresented on chromosomes 1, 6, 9, 10, and 14. Based on functional enrichment analysis, we selected LIM domain and actin binding 1 (LIMA1), tissue inhibitor of metalloproteinases 3 (TIMP3), cyclin-dependent kinases regulatory subunit 2 (CKS2), leptin receptor (LEPR), and baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) for validation using qPCR and confirmed their differential expression in the two groups of tumors. We calculated ΔCt values of CKS2 and LEPR and found that their differential expression (C-L index) was significantly higher in grade I than in grade II or III meningiomas (p

Original languageEnglish
Pages (from-to)1440-1450
Number of pages11
JournalThe oncologist
Volume16
Issue number10
DOIs
Publication statusPublished - 2011

    Fingerprint

Keywords

  • Cyclin kinase
  • DNA microarray
  • Leptin receptor
  • Loss of heterozygosity
  • Meningiomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this